South Carolina Department of Health and Human Services
CHIPRA Quality Demonstration Grant

Focus of Quality Measures - January 2011

Emergency Department Utilization:
Average number of emergency room visits per member per reporting period.

Well-Child Visits – First 15 months of life
This is an NCQA measure as well as a HEDIS measure. Although CHIPRA has well child visits listed with three components, for this Learning Collaborative, we will be focusing on the Well-Child Visits in the first 15 months of life.

Rates of screening using standardized screening tools for potential delays in social and emotional development
1) Screening Occurrence: Proportion of children who have had a standardized, validated developmental screening assessment at their 9, 18 or 30 month well-child visit within past 12 months
2) Abnormal Screening Result: proportion of children with an abnormal screening results documented on their problem list within the past 12 months.
3) Specialist follow-up proportion of children seen by specialist for developmental concerns within the past 12 months who had their specialist note reviewed by their primary clinician

NOTE: this quality measure will be re-visited later in the grant to include screenings for emotional development.

Follow-up care for children prescribed attention-deficit/hyperactivity disorder (ADHD) medication
The percentage of children newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication who have at least three follow-up care visits within a 10-month period, one of which is within 30 days of when the first ADHD medication was dispensed. Two rates are reported.
1. Initiation Phase. The percentage of members 6–12 years of age as of the IPSD with an ambulatory prescription dispensed for ADHD medication, who had one follow-up visit with practitioner with prescribing authority during the 30-day Initiation Phase.
2. Continuation and Maintenance (C&M) Phase. The percentage of members 6–12 years of age as of the IPSD with an ambulatory prescription dispensed for ADHD medication, who remained on the medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.